Longeveron Inc. (LGVN) NASDAQ

1.58

+0.02(+1.28%)

Updated at July 30 04:00PM

Currency In USD

Longeveron Inc.

Address

1951 NW 7th Avenue

Miami, FL 33136

United States of America

Phone

305 909 0840

Sector

Healthcare

Industry

Biotechnology

Employees

25

First IPO Date

February 12, 2021

Key Executives

NameTitlePayYear Born
Mr. Mohamed Wa'el Ahmed Hashad M.B.A.Chief Executive Officer & Director1.01M1962
Dr. Joshua Michael Hare FACC, M.D.Co-Founder, Chief Science Officer & Chairman600,6221963
Ms. Lisa A. Locklear M.B.A.Chief Financial Officer, Executive Vice President & Treasurer653,3911962
Mr. Paul T. Lehr J.D.General Counsel & Secretary748,5141968
Ms. Lisa McClain-MossVice President of Manufacturing01971
Mr. Devin BlassChief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls01986
Ms. Heather ZhouVice President & Corporate Controller0N/A
Dr. Nataliya Agafonova M.D.Chief Medical Officer01970
Mr. Brian G Rash Ph.D.Vice President of Research & Discovery0N/A

Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.